Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Infect Immun ; 87(4)2019 04.
Artículo en Inglés | MEDLINE | ID: mdl-30642899

RESUMEN

Members of the Mycobacterium avium complex (MAC) are characterized as nontuberculosis mycobacteria and are pathogenic mainly in immunocompromised individuals. MAC strains show a wide genetic variability, and there is growing evidence suggesting that genetic differences may contribute to a varied immune response that may impact the infection outcome. The current study aimed to characterize the genomic changes within M.avium isolates collected from single patients over time and test the host immune responses to these clinical isolates. Pulsed-field gel electrophoresis and whole-genome sequencing were performed on 40 MAC isolates isolated from 15 patients at the Department of Medical Microbiology at St. Olavs Hospital in Trondheim, Norway. Isolates from patients (patients 4, 9, and 13) for whom more than two isolates were available were selected for further analysis. These isolates exhibited extensive sequence variation in the form of single-nucleotide polymorphisms (SNPs), suggesting that M. avium accumulates mutations at higher rates during persistent infections than other mycobacteria. Infection of murine macrophages and mice with sequential isolates from patients showed a tendency toward increased persistence and the downregulation of inflammatory cytokines by host-adapted M. avium strains. The study revealed the rapid genetic evolution of M. avium in chronically infected patients, accompanied by changes in the virulence properties of the sequential mycobacterial isolates.


Asunto(s)
Evolución Molecular , Variación Genética , Infección por Mycobacterium avium-intracellulare/microbiología , Mycobacterium avium/genética , Adaptación Biológica , Anciano , Anciano de 80 o más Años , Animales , Proteínas Bacterianas/genética , Proteínas Bacterianas/metabolismo , Células Cultivadas , Citocinas/genética , Citocinas/metabolismo , Femenino , Humanos , Macrófagos/microbiología , Masculino , Ratones , Ratones Endogámicos C57BL , Persona de Mediana Edad , Mycobacterium avium/fisiología , Infección por Mycobacterium avium-intracellulare/genética , Infección por Mycobacterium avium-intracellulare/metabolismo , Filogenia , Polimorfismo de Nucleótido Simple
2.
Tidsskr Nor Laegeforen ; 114(18): 2102-6, 1994 Aug 10.
Artículo en Noruego | MEDLINE | ID: mdl-7992265

RESUMEN

This report, which is based on laboratory reports and patient records, covers the epidemiology, etiology and antibiotic susceptibility of all bacteremic episodes at a community hospital during 1988-90. The overall incidence was eight episodes per 1000 patient admissions, though this figure varied considerably between departments and between age groups. Most organisms were community acquired, and we had few Klebsiella spp., Pseudomonas spp., anaerobic bacteria, fungi and polymicrobial episodes. There were fewer antibiotic resistant strains than reported from outside Scandinavia. The combination of benzylpenicillin and aminoglycoside (plus metronidazole in surgical wards) has a broad enough spectrum of activity for 95% of our patients with sepsis of unknown origin. Thus, our rather "old-fashioned" prescribing policy, with the new and broadspectrum cephalosporins and betalactam drugs constituting only a minor part, is still good practice. The study also shows that cumulative reports issued by the local microbiological laboratory bring awareness to these issues and affect the prescribing pattern in a positive way.


Asunto(s)
Bacteriemia/epidemiología , Infección Hospitalaria/epidemiología , Adulto , Antibacterianos/administración & dosificación , Bacteriemia/tratamiento farmacológico , Bacteriemia/microbiología , Niño , Infección Hospitalaria/tratamiento farmacológico , Infección Hospitalaria/microbiología , Farmacorresistencia Microbiana , Hospitales de Distrito/estadística & datos numéricos , Humanos , Lactante , Noruega/epidemiología
3.
Eur Respir J ; 3(1): 27-32, 1990 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-2311727

RESUMEN

Enprofylline, a drug without adenosine antagonism and theophylline, a potent adenosine antagonist, were compared, double-blind, randomized, in acute asthma (n = 33). The drugs were given intravenously as loading over 10 min followed by maintenance infusion for 24 h. Mean final plasma levels were very high with enprofylline (14 mg.l), and larger than calculated with theophylline (16 mg.l). Seven patients had maximum levels of enprofylline ranging between 16 and 42 mg.l. Extreme plasma levels of enprofylline were not associated with any theophylline-like central nervous system excitatory effects related to seizure-inducing ability. Some irregularities in the heart rhythm did not raise clinical problems and no significant difference between enprofylline and theophylline was recorded. At 1 h patients on enprofylline (mean plasma level: 5.7 mg.l) and theophylline (12.2 mg.l) had improved their peak expiratory flow rates by 31% and 15% (p less than 0.05), respectively. The improvement in lung function after 24 hours did not differ between treatments suggesting that the high levels of enprofylline were supramaximal for its anti-asthma effects in this situation. In conclusion, with enprofylline it is demonstrated that an adenosine non-blocking xanthine derivative may lack CNS-excitatory effects, but be more potent than theophylline in the treatment of acute asthma.


Asunto(s)
Asma/tratamiento farmacológico , Broncodilatadores/uso terapéutico , Teofilina/uso terapéutico , Xantinas/uso terapéutico , Enfermedad Aguda , Adolescente , Adulto , Anciano , Arritmias Cardíacas/inducido químicamente , Broncodilatadores/efectos adversos , Broncodilatadores/sangre , Broncodilatadores/farmacología , Método Doble Ciego , Evaluación de Medicamentos , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Humanos , Masculino , Persona de Mediana Edad , Ápice del Flujo Espiratorio/efectos de los fármacos , Distribución Aleatoria , Teofilina/efectos adversos , Teofilina/sangre , Teofilina/farmacología , Xantinas/efectos adversos , Xantinas/sangre , Xantinas/farmacología
4.
5.
Lancet ; 2(8566): 1027, 1987 Oct 31.
Artículo en Inglés | MEDLINE | ID: mdl-2889935
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA